PASG vs PDSB

Passage Bio, Inc. vs PDS Biotechnology Corporation — Valuation Comparison 2026

PASG

Biotechnology
Passage Bio, Inc.
Quality
3.9
out of 10
Value Trap
24
SAFE
Price
$5.71
Last close
Models
7/13
Active
VS

PDSB

Biotechnology
PDS Biotechnology Corporation
Quality
4.0
out of 10
Value Trap
30
LOW
Price
$1.07
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType PASG Fair ValuePASG Upside PDSB Fair ValuePDSB Upside
Bayesian DCF Intrinsic $3.83 -33.0% $0.50 -53.6%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $30.86 +440.5% $0.63 -40.9%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for PASG vs PDSB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PASG vs PDSB — Which Stock Is More Undervalued?

PDSB scores higher with a 4.0/10 quality rating vs PASG's 3.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Passage Bio, Inc. (PASG) and PDS Biotechnology Corporation (PDSB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PASG currently trades at $5.71 with a QOC of 3.9/10, while PDSB trades at $1.07 with a QOC of 4.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).